Read by QxMD icon Read

Jones, olcay

Gulnara Mamyrova, Lisa G Rider, Alison Ehrlich, Olcay Jones, Lauren M Pachman, Robert Nickeson, Lisa G Criscone-Schreiber, Lawrence K Jung, Frederick W Miller, James D Katz
Objective: The aim was to assess environmental factors associated with disease flare in juvenile and adult dermatomyositis (DM). Methods: An online survey of DM patients from the USA and Canada examined smoking, sun exposure, infections, medications, vaccines, stressful life events and physical activity during the 6 months before flares, or in the past 6 months in patients without flares. Differences were evaluated by χ 2 and Fisher's exact tests, and significant univariable results were examined in multivariable logistic regression...
August 1, 2017: Rheumatology
Y Liu, A A Jesus, B Marrero, D Yang, S E Ramsey, G A Montealegre Sanchez, K Tenbrock, H Wittkowski, O Y Jones, H S Kuehn, C-C R Lee, M A DiMattia, E W Cowen, B Gonzalez, I Palmer, J J DiGiovanna, A Biancotto, H Kim, W L Tsai, A M Trier, Y Huang, D L Stone, S Hill, H J Kim, C St Hilaire, S Gurprasad, N Plass, D Chapelle, I Horkayne-Szakaly, D Foell, A Barysenka, F Candotti, S M Holland, J D Hughes, H Mehmet, A C Issekutz, M Raffeld, J McElwee, J R Fontana, C P Minniti, S Moir, D L Kastner, M Gadina, A C Steven, P T Wingfield, S R Brooks, S D Rosenzweig, T A Fleisher, Z Deng, M Boehm, A S Paller, R Goldbach-Mansky
BACKGROUND: The study of autoinflammatory diseases has uncovered mechanisms underlying cytokine dysregulation and inflammation. METHODS: We analyzed the DNA of an index patient with early-onset systemic inflammation, cutaneous vasculopathy, and pulmonary inflammation. We sequenced a candidate gene, TMEM173, encoding the stimulator of interferon genes (STING), in this patient and in five unrelated children with similar clinical phenotypes. Four children were evaluated clinically and immunologically...
August 7, 2014: New England Journal of Medicine
Olcay Y Jones, Faysal Gok, Elisabeth J Rushing, Iren Horkayne-Szakaly, Atif A Ahmed
Somatic tissue engraftment was studied in BXSB mice treated with mesenchymal stem cell transplantation. Hosts were conditioned with nonlethal radiation prior to introducing donor cells from major histocompatibility complex-matched green fluorescent protein transgenic mice. Transplant protocols differed for route of injection, ie, intravenous (i.v.) versus intraperitoneal (i.p.), and source of mesenchymal stem cells, ie, unfractionated bone marrow cells, ex vivo expanded mesenchymal stem cells, or bone chips...
2011: Stem Cells and Cloning: Advances and Applications
Lisa G Rider, James D Katz, Olcay Y Jones
This review updates recent trends in the classification of the juvenile idiopathic inflammatory myopathies (JIIM) and the emerging standard of treatment of the most common form of JIIM, juvenile dermatomyositis. The JIIM are rare, heterogeneous autoimmune diseases that share chronic muscle inflammation and weakness. A growing spectrum of clinicopathologic groups and serologic phenotypes defined by the presence of myositis autoantibodies are now recognized, each with differing demographics, clinical manifestations, laboratory findings, and prognoses...
November 2013: Rheumatic Diseases Clinics of North America
Gulnara Mamyrova, James D Katz, Robert V Jones, Ira N Targoff, Peter A Lachenbruch, Olcay Y Jones, Frederick W Miller, Lisa G Rider
OBJECTIVE: To differentiate juvenile polymyositis (PM) and muscular dystrophy, both of which may present with chronic muscle weakness and inflammation. METHODS: We studied 39 patients with probable or definite juvenile PM and 9 patients with muscular dystrophies who were initially misdiagnosed as having juvenile PM. Differences in demographic, clinical, and laboratory results; outcomes; and treatment responses were evaluated by Fisher's exact and rank sum tests...
December 2013: Arthritis Care & Research
Bita Arabshahi, Robert A Silverman, Olcay Y Jones, Lisa G Rider
We report the successful use of abatacept and sodium thiosulfate in a patient with severe recalcitrant juvenile dermatomyositis complicated by ulcerative skin disease and progressive calcinosis. This combination therapy resulted in significant reductions in muscle and skin inflammation, decreased corticosteroid dependence, and halted the progression of calcinosis.
March 2012: Journal of Pediatrics
Rina Mina, Emily von Scheven, Stacy P Ardoin, B Anne Eberhard, Marilynn Punaro, Norman Ilowite, Joyce Hsu, Marisa Klein-Gitelman, L Nandini Moorthy, Eyal Muscal, Suhas M Radhakrishna, Linda Wagner-Weiner, Matthew Adams, Peter Blier, Lenore Buckley, Elizabeth Chalom, Gaëlle Chédeville, Andrew Eichenfield, Natalya Fish, Michael Henrickson, Aimee O Hersh, Roger Hollister, Olcay Jones, Lawrence Jung, Deborah Levy, Jorge Lopez-Benitez, Deborah McCurdy, Paivi M Miettunen, Ana I Quintero-del Rio, Deborah Rothman, Ornella Rullo, Natasha Ruth, Laura E Schanberg, Earl Silverman, Nora G Singer, Jennifer Soep, Reema Syed, Larry B Vogler, Ali Yalcindag, Cagri Yildirim-Toruner, Carol A Wallace, Hermine I Brunner
OBJECTIVE: To formulate consensus treatment plans (CTPs) for induction therapy of newly diagnosed proliferative lupus nephritis (LN) in juvenile systemic lupus erythematosus (SLE). METHODS: A structured consensus formation process was employed by the members of the Childhood Arthritis and Rheumatology Research Alliance after considering the existing medical evidence and current treatment approaches. RESULTS: After an initial Delphi survey (response rate = 70%), a 2-day consensus conference, and 2 followup Delphi surveys (response rates = 63-79%), consensus was achieved for a limited set of CTPs addressing the induction therapy of proliferative LN...
March 2012: Arthritis Care & Research
James D Katz, Gulnara Mamyrova, Shilpi Agarwal, Olcay Y Jones, Harriet Bollar, Adam M Huber, Lisa G Rider, Patience H White
BACKGROUND: Children with complex medical issues experience barriers to the transition of care from pediatric to adult providers. We sought to identify these barriers by elucidating the experiences of patients with idiopathic inflammatory muscle disorders. METHODS: We collected anonymous survey data using an online website. Patients and their families were solicited from the US and Canada through established clinics for children with idiopathic inflammatory muscle diseases as well as with the aid of a nonprofit organization for the benefit of such individuals...
June 7, 2011: Pediatric Rheumatology Online Journal
Olcay Y Jones, A Lacson, X Zeng, J M Jones, K Katti, R A Cahill, A A Ahmed
We present long-term outcomes of BXSB mice after non-myeloablative bone marrow transplants using major histocompatability complex (MHC)-matched cells. Groups differed in sources of donor lymphocytes or mesenchymal stromal cells (MSC). Unfractionated marrow cells from green fluorescent protein (GFP) transgenic (Tg) mice (BMT group) or from RAG1-/- B6 mice (RAG group) were injected intravenously (i.v.) into irradiated (550 cGy) hosts. As a source of mesenchymal cells, bone chips from GFP-Tg were injected intraperitoneally alone (MSC group) or along with i...
August 2009: Lupus
Olcay Y Jones, Richard A Cahill
No abstract text is available yet for this article.
2008: Immunologic Research
Olcay Y Jones, Daniel J Lovell
No abstract text is available yet for this article.
September 2006: Nature Clinical Practice. Rheumatology
Daniel J Lovell, Andreas Reiff, Olcay Y Jones, Rayfel Schneider, James Nocton, Leonard D Stein, Abraham Gedalia, Norman T Ilowite, Carol A Wallace, James B Whitmore, Barbara White, Edward H Giannini et al.
OBJECTIVE: Previous studies showed that etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA) provided rapid clinical improvement that was sustained for up to 2 years. The goal of our study was to provide data on safety and efficacy after 4 years of etanercept treatment in patients with JRA. METHODS: Patients with active polyarticular-course JRA who participated in an efficacy study continued etanercept treatment in an open-label extension...
June 2006: Arthritis and Rheumatism
Olcay Y Jones, Charles H Spencer, Suzanne L Bowyer, Peter B Dent, Beth S Gottlieb, C Egla Rabinovich
OBJECTIVE: Acute lymphocytic leukemia (ALL) often presents with musculoskeletal concerns such as pain or swelling, even before appearance of blasts in the peripheral blood. Such presentation may lead to misdiagnosis of a child with juvenile rheumatoid arthritis (JRA). This study was designed to identify the predictive factors for leukemia using basic clinical and laboratory information. METHODS: A retrospective chart review was performed using a simple questionnaire to compare the clinical and laboratory findings present during the initial visit to a pediatric rheumatology clinic for 277 children who were ultimately diagnosed with either JRA (n = 206) or ALL (n = 71)...
May 2006: Pediatrics
Laura J Mirkinson, David Nagle, Nadja Kadom, Olcay Y Jones
A 3-year-old patient with biopsy-proven herpesvirus 6 (HHV-6) encephalitis developed a clinical condition consistent with systemic-onset juvenile idiopathic rheumatoid arthritis (SoJIA) and responsive to synthetic interleukin-1 (IL-1) receptor therapy. This suggested both a temporal relationship between HHV-6 infection and the development of SoJIA and the likely involvement of IL-1 in his disease. This case adds to the current experience of IL-1 receptor antagonist therapy in SoJIA. In addition, it suggests that future prospective studies in new-onset SoJIA should include an evaluation for HHV-6 infection...
April 2006: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
Richard A Cahill, Olcay Y Jones, Martin Klemperer, Anne Steele, Thomas O Mueller, Nagwa el-Badri, Y Chang, Robert A Good
Abstract We present our experience on treatment of three children with potentially fatal diseases using a unique protocol for non-myeloablative bone marrow transplantation. The protocol was designed to promote engraftment of bone marrow stromal/mesenchymal cells (SC/MSCs) based on the knowledge from preclinical models over the last three decades. Accordingly, our protocol is the first to test the use of bone fragments as an ideal vehicle to transplant such cells residing in the bone core. Because of the paucity of knowledge for optimum transplantation of SC/MSCs in humans, we used a multifaceted approach and implanted bone fragments both intraperitoneally and directly into bone on day 0 of BMT...
October 2004: Biology of Blood and Marrow Transplantation
Olcay Y Jones, Ann Steele, Joe M Jones, Yasmin Marikar, Yenhui Chang, Alexander Feliz, Richard A Cahill, Robert A Good
Male BXSB mice, a mouse model of systemic lupus erythematosus, were given bone marrow transplants (BMT) at 20 wk of age using MHC-matched donor cells and nonmyeloablative conditioning (550 cGy irradiation). Transplanted mice and irradiation controls were followed for a period of 20 wk. Mice transgenic for green fluorescent protein were used as donors to allow tracking of donor cells and a determination of chimerism. Radiation controls had reduced renal pathology at 10 wk posttransplant, but not at 20 wk compared with untreated mice, while nonmyeloablative BMT mice had significantly reduced pathology at both time intervals...
May 1, 2004: Journal of Immunology: Official Journal of the American Association of Immunologists
Nutthapong Tangsinmankong, Hyder A Khan, Olcay Y Jones, Robert A Good
No abstract text is available yet for this article.
May 2003: Annals of Allergy, Asthma & Immunology
Daniel J Lovell, Edward H Giannini, Andreas Reiff, Olcay Y Jones, Rayfel Schneider, Judyann C Olson, Leonard D Stein, Abraham Gedalia, Norman T Ilowite, Carol A Wallace, Mary Lange, Barbara K Finck, Daniel J Burge et al.
OBJECTIVE: To evaluate the long-term efficacy and safety of etanercept in children with juvenile rheumatoid arthritis (JRA) participating in an ongoing multicenter, open-label, extended-treatment trial. All patients had been participants in an initial randomized efficacy and safety trial of etanercept. METHODS: Etanercept was administered at a dosage of 0.4 mg/kg (maximum 25 mg) subcutaneously twice each week. Safety and efficacy evaluations were performed every 3-4 months...
January 2003: Arthritis and Rheumatism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"